

**TRANSMITTAL FORM**

(for all correspondence after initial filing)

Total number of pages in this submission =

Application # 10/661,809

Confirmation # 7385

Filing Date 15 September 2003

First Inventor HOOK et al

Art Unit 1631

Examiner Smith, Carolyn L.

Docket # P07741US01/BAS

ENCLOSURES (check all that apply)

- | | |
|--|--|
| <input checked="" type="checkbox"/> Fees calculated below | <input type="checkbox"/> Reply to Missing Parts/Incomplete Application |
| <input checked="" type="checkbox"/> Amendment/Reply | <input type="checkbox"/> Certified Copy of Priority Document(s) |
| <input checked="" type="checkbox"/> including Attachments | <input checked="" type="checkbox"/> Information Disclosure Statement |
| <input type="checkbox"/> After Final Amendment/Reply | <input type="checkbox"/> Drawing(s) |
| <input type="checkbox"/> including Attachment(s) | <input type="checkbox"/> Terminal Disclaimer |
| <input checked="" type="checkbox"/> Extension of Time Petition | <input type="checkbox"/> |
| <input type="checkbox"/> | <input type="checkbox"/> |

FEES CALCULATION: For claims if required and/or other fees as shown below:

	NOW	Previously Paid For	Present Extra	Rate	\$
<input checked="" type="checkbox"/> TOTAL CLAIMS	39	- 40	0	X \$ 50 =	0
<input checked="" type="checkbox"/> INDEPENDENT CLAIMS	6	- 4	2	X \$ 200 =	400
TOTAL OF ABOVE CLAIMS FEES =					400
<input checked="" type="checkbox"/> Reduction by ½ for small entity status of applicant					200
<input checked="" type="checkbox"/> Fee for extension of time (per attached Petition)					200
<input type="checkbox"/> Other fee for					510
TOTAL OF ALL FEES =					\$710

- Payment by credit card. FORM PTO-2038 in the amount of \$710 is attached.
- The Director is authorized to charge any fee, additional fee or extension fee due in connection herewith to Deposit Account No. 12-0555:
(1) if no payment or an insufficient payment is enclosed and a fee is due in connection herewith; or
(2) if no petition for extension of time is enclosed but an EOT is required - and in this event, applicant hereby petitions under 37 CFR 1.136(a) for an extension of time of as many months as are required to render this submission timely.

Date: February 16, 2007

By: B. Aaron Schulman
Registration No.: 31,877STITES & HARBISON PLLC • 1199 North Fairfax St. • Suite 900 • Alexandria, VA 22314
TEL: 703-739-4900 • FAX: 703-739-9577 • Customer No. 00881



Addendum

Attachment 1

SYSTEM AND METHOD FOR OLAP REPORT GENERATION WITH SPREADSHEET
REPORT WITHIN THE NETWORK USER INTERFACE



SYNOPSIS OF APPLICATION OF WRITTEN DESCRIPTION

GUIDELINES

Contents

COPY

Overview	2
Decision Trees	
Written Description Amended or New Claims or Claims	
Asserting the Benefit of an Earlier Filing Date ...	4
Original Claims	5
Example 1: Amended claims	3
Example 2: 35 USC 120 Priority	6
Example 2A: Essential element missing	
from original claim	8
Example 2B: A preferred element missing from original claim	10
Example 3: New claims	12
Example 4: Original claim	15
Example 5: Flow Diagrams	17

Example 6: Genes	20
------------------------	----

Example 7: EST	23
----------------------	----

Example 8: DNA Fragment Encoding a Full length	
--	--

COPY

Open Reading Frame (ORF)	26
--------------------------------	----

Example 9: Hybridization	28
--------------------------------	----

Example 10: Process Claim	31
---------------------------------	----

Example 11: Allelic Variant	33
-----------------------------------	----

Example 12: Bioinformatics	40
----------------------------------	----

Example 13: Protein Variant	43
-----------------------------------	----

Example 14: Product by Function	46
---------------------------------------	----

Example 15: Antisense	49
-----------------------------	----

→ Example 16: Antibodies	52
--------------------------------	----


Example 17: Genus-species with widely varying	
---	--

species.....	54
--------------	----

Example 18: Process claim where the novelty is in the	
---	--

method steps 58

COPY



Example 16: Antibodies

Specification: The specification teaches that antigen X has been isolated and is useful for detection of HIV infections. The specification teaches antigen X as purified by gel filtration and provides characterization of the antigen as having a molecular weight of 55 KD. The specification also provides a clear protocol by which antigen X was isolated. The specification contemplates but does not teach in an example antibodies which specifically bind to antigen X and asserts that these antibodies can be used in immunoassays to detect HIV. The general knowledge in the art is such that antibodies are structurally well characterized. It is well known that all mammals produce antibodies and they exist in five isotypes, IgM, IgG, IgD, IgA and IgE. Antibodies contain an effector portion which is the constant region and a variable region that contains the antigen binding sites in the form of complementarity determining regions and the framework regions. The sequences of constant regions as well as the variable regions subgroups (framework regions) from a variety of species are known and published in the art. It is also well known that antibodies can be made against virtually any protein.

→ **Claim:** An isolated antibody capable of binding to antigen X.

Analysis:

A review of the full content of the specification indicates that antibodies which bind to antigen X are essential to the operation of the claimed invention. The level of skill and knowledge in the art of antibodies at the time of filing was such that production of antibodies against a well-

characterized antigen was conventional. This is a mature technology where the level of skill is high and advanced.

The claim is directed to any antibody which is capable of binding to antigen X.

A search of the prior art indicates that antigen X is novel and unobvious.

Considering the routine art-recognized method of making antibodies to fully characterized antigens, the well defined structural characteristics for the five classes of antibody, the functional characteristics of antibody binding, and the fact that the antibody technology is well developed and mature, one of skill in the art would have recognized that the spectrum of antibodies which bind to antigen X were implicitly disclosed as a result of the isolation of antigen X.

- **Conclusion:** The disclosure meets the requirement under 35 USC 112 first paragraph as providing an adequate written description of the claimed invention.